Endpoints News2d
BioN­Tech de­tails promis­ing mid-stage da­ta for its PD-L1xVEGF in ag­gres­sive lung can­cer
BioNTech's BNT327 shows promising survival data in lung cancer trial, with 72.7% of patients surviving one year, ...
KMA Radio5d
Finding alternatives for Dicamba
Maintaining a stable weed control program is always a challenge, and the upcoming loss of Dicamba for growers in 2025 adds another layer of difficulty. Without this key tool, farmers ...